GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines. With 30 crore prescriptions annually, GSK aims to innovate and grow its portfolio, highlighting price strategies catering to a broad market range, from general medicines to high-value therapies.
Related Posts
Share of loans for homes valued at Rs 75L+ grows 1.5x in 4 years
Residential real estate sales in India are being driven by premium and luxury housing, with home loans for properties valued at Rs 75 lakh and […]
Peak XV cuts $2.8 billion startup fund by 16%
Peak XV Partners has reduced its $2.8-billion fund for India and Southeast Asia by 16% due to high valuations in private markets, particularly affecting late-stage […]